Form 8-K - Current report:
SEC Accession No. 0000950170-25-028323
Filing Date
2025-02-27
Accepted
2025-02-27 06:34:38
Documents
14
Period of Report
2025-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nuvl-20250227.htm   iXBRL 8-K 48326
2 EX-99.1 nuvl-ex99_1.htm EX-99.1 119844
3 GRAPHIC img8926856_0.jpg GRAPHIC 26288
4 GRAPHIC img8926856_1.jpg GRAPHIC 26288
  Complete submission text file 0000950170-25-028323.txt   375419

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nuvl-20250227.xsd EX-101.SCH 31924
16 EXTRACTED XBRL INSTANCE DOCUMENT nuvl-20250227_htm.xml XML 4703
Mailing Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 508-446-2272
Nuvalent, Inc. (Filer) CIK: 0001861560 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40671 | Film No.: 25672703
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)